These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 2857143)
1. Influence of growth hormone on overnight insulin requirements in insulin-dependent diabetes. Skor DA; White NH; Thomas L; Santiago JV Diabetes; 1985 Feb; 34(2):135-9. PubMed ID: 2857143 [TBL] [Abstract][Full Text] [Related]
2. Relative roles of insulin clearance and insulin sensitivity in the prebreakfast increase in insulin requirements in insulin-dependent diabetic patients. Skor DA; White NH; Thomas L; Santiago JV Diabetes; 1984 Jan; 33(1):60-3. PubMed ID: 6360768 [TBL] [Abstract][Full Text] [Related]
3. Examination of the role of the pituitary-adrenocortical axis, counterregulatory hormones, and insulin clearance in variable nocturnal insulin requirements in insulin-dependent diabetes. Skor DA; White NH; Thomas L; Shah SD; Cryer PE; Santiago JV Diabetes; 1983 May; 32(5):403-7. PubMed ID: 6341122 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of somatostatin in regulating pancreatic splenic lobe hormone secretion following 99% pancreatectomy in adult chickens. Cieslak SR; Hazelwood RL Gen Comp Endocrinol; 1986 Aug; 63(2):284-94. PubMed ID: 2877920 [TBL] [Abstract][Full Text] [Related]
5. Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man. MacGorman LR; Rizza RA; Gerich JE J Clin Endocrinol Metab; 1981 Sep; 53(3):556-9. PubMed ID: 6114964 [TBL] [Abstract][Full Text] [Related]
6. Insulin clearance contributes to the variability of nocturnal insulin requirement in insulin-dependent diabetes mellitus. Dux S; White NH; Skor DA; Santiago JV Diabetes; 1985 Dec; 34(12):1260-5. PubMed ID: 3905459 [TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. Campbell PJ; Bolli GB; Cryer PE; Gerich JE N Engl J Med; 1985 Jun; 312(23):1473-9. PubMed ID: 2859524 [TBL] [Abstract][Full Text] [Related]
8. Effects of amino acids on glucose disposal. Boden G; Tappy L Diabetes; 1990 Sep; 39(9):1079-84. PubMed ID: 1974539 [TBL] [Abstract][Full Text] [Related]
9. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Perriello G; De Feo P; Torlone E; Fanelli C; Santeusanio F; Brunetti P; Bolli GB Diabetologia; 1990 Jan; 33(1):52-9. PubMed ID: 2406181 [TBL] [Abstract][Full Text] [Related]
10. Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men. D'Alessio DA; Ensinck JW Diabetes; 1990 Oct; 39(10):1198-202. PubMed ID: 1976558 [TBL] [Abstract][Full Text] [Related]
12. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. Rizza RA; Cryer PE; Gerich JE J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413 [TBL] [Abstract][Full Text] [Related]
13. Extrapancreatic effect of somatostatin infusion to increase glucose clearance. Bergman RN; Ader M; Finegood DT; Pacini G Am J Physiol; 1984 Sep; 247(3 Pt 1):E370-9. PubMed ID: 6148014 [TBL] [Abstract][Full Text] [Related]
14. The pancreatic glucagon and C-peptide secretion during hyperinsulinemia in euglycemic glucose clamp with or without somatostatin infusion in normal man. Wu MS; Ho LT Horm Metab Res; 1987 Jun; 19(6):253-6. PubMed ID: 2887501 [TBL] [Abstract][Full Text] [Related]
15. Glucagon does not increase plasma free fatty acid and glycerol concentrations in patients with noninsulin-dependent diabetes mellitus. Jeng CY; Sheu WH; Jaspan JB; Polonsky KS; Chen YD; Reaven GM J Clin Endocrinol Metab; 1993 Jul; 77(1):6-10. PubMed ID: 8100832 [TBL] [Abstract][Full Text] [Related]
16. Sexual dimorphism of somatostatin and growth hormone-releasing factor signaling in the control of pulsatile growth hormone secretion in the rat. Painson JC; Tannenbaum GS Endocrinology; 1991 Jun; 128(6):2858-66. PubMed ID: 1674685 [TBL] [Abstract][Full Text] [Related]
17. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Baron AD; Schaeffer L; Shragg P; Kolterman OG Diabetes; 1987 Mar; 36(3):274-83. PubMed ID: 2879757 [TBL] [Abstract][Full Text] [Related]
18. Short-term of the artificial beta-cell (Biostator) on pancreatic glucagon response in insulin-dependent diabetic (IDDM). Ratzmann KP; Schneider U; Besch W; Heinke P Exp Clin Endocrinol; 1984 Jul; 84(1):91-8. PubMed ID: 6383851 [TBL] [Abstract][Full Text] [Related]
19. Effects of somatostatin and glucose infusion on glucose kinetics in fetal sheep. Bloch CA; Menon RK; Sperling MA Am J Physiol; 1988 Jul; 255(1 Pt 1):E87-93. PubMed ID: 2898894 [TBL] [Abstract][Full Text] [Related]
20. Splanchnic metabolism of alanine in intact man. Effects of somatostatin and somatostatin plus insulin. Rabin D; Mueller GL; Lacy WW; Liljenquist JE Diabetes; 1979 May; 28(5):486-90. PubMed ID: 437378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]